State Street Corp Has $126,000 Stock Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA)

State Street Corp increased its position in shares of Lyra Therapeutics, Inc. (NASDAQ:LYRA) by 88.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 488,720 shares of the company’s stock after acquiring an additional 228,900 shares during the quarter. State Street Corp owned 0.75% of Lyra Therapeutics worth $126,000 as of its most recent SEC filing.

Separately, Acadian Asset Management LLC purchased a new position in Lyra Therapeutics during the 2nd quarter worth approximately $271,000. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Lyra Therapeutics Stock Down 3.7 %

LYRA opened at $0.21 on Friday. The firm has a market capitalization of $13.62 million, a P/E ratio of -0.14 and a beta of -0.12. The stock has a fifty day moving average of $0.21 and a 200-day moving average of $0.26. Lyra Therapeutics, Inc. has a 12-month low of $0.16 and a 12-month high of $6.79.

Lyra Therapeutics Profile

Lyra Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.